Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-year Results from a Comparative Effectiveness Randomized Clinical Trial

PURPOSE: Provide 2-year efficacy, safety and treatment results comparing three anti-vascular endothelial growth factor (anti-VEGF) agents for center-involved diabetic macular edema (DME) utilizing a standardized follow-up and retreatment regimen. DESIGN: Randomized clinical trial. PARTICIPANTS: 660...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Ophthalmology
Главные авторы: Wells, John A., Glassman, Adam R., Ayala, Allison R., Jampol, Lee M., Bressler, Neil M., Bressler, Susan B., Brucker, Alexander J., Ferris, Frederick L., Hampton, G. Robert., Jhaveri, Chirag, Melia, Michele, Beck, Roy W.
Формат: Artigo
Язык:Inglês
Опубликовано: 2016
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4877252/
https://ncbi.nlm.nih.gov/pubmed/26935357
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ophtha.2016.02.022
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы